Literature DB >> 30617966

Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies.

Huijuan Wang1, Shuhong Zhou2, Jiahong Zhang2, Shangwen Lei2, Jing Zhou2.   

Abstract

Recently, the roles of toll-like receptor (TLR) polymorphisms in inflammatory bowel disease (IBD) were intensively explored, with conflicting results. Therefore, we performed this study to better assess the relationship between TLR polymorphisms and the risk of IBD. Eligible studies were searched in PubMed, Medline, Embase, and Web of Science. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate associations between TLR polymorphisms and IBD. Significant associations with the risk of IBD were detected for the TLR1 rs5743611, TLR4 rs4986790, TLR4 rs4986791, and TLR6 rs5743810 polymorphisms in overall analyses. Further subgroup analyses according to ethnicity of participants revealed that the TLR1 rs5743611, TLR4 rs4986790, TLR4 rs4986791, TLR6 rs5743810, and TLR9 rs352140 polymorphisms were significantly associated with the risk of IBD in Caucasians. Moreover, the TLR4 rs4986790 polymorphism was significantly correlated with the risk of IBD in West Asians, while the TLR9 rs352140 polymorphism was significantly associated with the risk of IBD in Africans. When we stratified available data according to type of disease, we found similar positive results for TLR1 rs5743611, TLR4 rs4986790, TLR4 rs4986791, and TLR6 rs5743810 polymorphisms. Our findings indicate that TLR1 rs5743611, TLR4 rs4986790, TLR4 rs4986791, TLR6 rs5743810, and TLR9 rs352140 polymorphisms may serve as genetic biomarkers of IBD in certain ethnicities. However, further well-designed studies are still warranted to confirm our findings.

Entities:  

Keywords:  Crohn’s disease (CD); Gene polymorphisms; Inflammatory bowel disease (IBD); Meta-analysis; Toll-like receptor (TLR); Ulcerative colitis (UC)

Mesh:

Substances:

Year:  2019        PMID: 30617966     DOI: 10.1007/s12026-018-9061-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  15 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  Recognition and signaling by toll-like receptors.

Authors:  A Phillip West; Anna Alicia Koblansky; Sankar Ghosh
Journal:  Annu Rev Cell Dev Biol       Date:  2006       Impact factor: 13.827

3.  Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases.

Authors:  Marie Pierik; Sofie Joossens; Kristel Van Steen; Nele Van Schuerbeek; Robert Vlietinck; Paul Rutgeerts; Severine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

4.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

Review 5.  Cytokines in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

6.  Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2.

Authors:  C Abad; M F González-Escribano; L M Diaz-Gallo; J M Lucena-Soto; J L Márquez; E Leo; C Crivell; M Gómez-García; J Martín; A Núñez-Roldán; J R García-Lozano
Journal:  Genes Immun       Date:  2011-06-30       Impact factor: 2.676

Review 7.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

Review 8.  Antibody markers in the diagnosis of inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Hidetoshi Takedatsu; Hiroshi Yamasaki; Kotaro Kuwaki; Shinichiro Yoshioka; Ryosuke Yamauchi; Shuhei Fukunaga; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 9.  Inflammatory bowel disease: etiology, pathogenesis and current therapy.

Authors:  Joshua K Ko; Kathy K Auyeung
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 10.  TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease.

Authors:  Romain Altwegg; Thierry Vincent
Journal:  Mediators Inflamm       Date:  2014-03-18       Impact factor: 4.711

View more
  5 in total

1.  Overall corrections and assessments of "Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies".

Authors:  Morteza Gholami; Mahsa M Amoli; Farshad Sharifi
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

2.  Expression of TLR2 and TLR5 in distal ileum of mice with obstructive jaundice and their role in intestinal mucosal injury.

Authors:  Xiaopeng Tian; Zixuan Zhang; Wen Li
Journal:  Arch Med Sci       Date:  2019-06-04       Impact factor: 3.318

Review 3.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

4.  Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma-A Single-Center Study.

Authors:  Theodoros Androutsakos; Athanasios-Dimitrios Bakasis; Abraham Pouliakis; Maria Gazouli; Christos Vallilas; Gregorios Hatzis
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

5.  NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium.

Authors:  Jose Manuel Sánchez-Maldonado; Manuel Martínez-Bueno; Helena Canhão; Rob Ter Horst; Sonia Muñoz-Peña; Ana Moñiz-Díez; Ana Rodríguez-Ramos; Alejandro Escudero; Signe B Sorensen; Merete L Hetland; Miguel A Ferrer; Bente Glintborg; Ileana Filipescu; Eva Pérez-Pampin; Pablo Conesa-Zamora; Antonio García; Alfons den Broeder; Salvatore De Vita; Svend Erik Hove Jacobsen; Eduardo Collantes; Luca Quartuccio; Mihai G Netea; Yang Li; João E Fonseca; Manuel Jurado; Miguel Ángel López-Nevot; Marieke J H Coenen; Vibeke Andersen; Rafael Cáliz; Juan Sainz
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.